(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 93.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Lenz Therapeutics's revenue in 2025 is $17,500,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2025 to be $548,200,257, with the lowest LENZ revenue forecast at $183,985,018, and the highest LENZ revenue forecast at $709,187,147. On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,668,005,667, with the lowest LENZ revenue forecast at $1,262,456,379, and the highest LENZ revenue forecast at $1,990,824,278.
In 2027, LENZ is forecast to generate $4,242,919,796 in revenue, with the lowest revenue forecast at $3,670,626,263 and the highest revenue forecast at $4,599,625,443.